- Home
- ENTG vs MRNA Comparison
ENTG vs MRNA Comparison
Compare ENTG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTG
- MRNA
- Stock Information
- Founded
- ENTG 1966
- MRNA 2010
- Country
- ENTG United States
- MRNA United States
- Employees
- ENTG N/A
- MRNA N/A
- Industry
- ENTG Plastic Products
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTG Industrials
- MRNA Health Care
- Exchange
- ENTG Nasdaq
- MRNA Nasdaq
- Market Cap
- ENTG 12.2B
- MRNA 11.1B
- IPO Year
- ENTG 2000
- MRNA 2018
- Fundamental
- Price
- ENTG $86.94
- MRNA $32.79
- Analyst Decision
- ENTG Strong Buy
- MRNA Hold
- Analyst Count
- ENTG 9
- MRNA 19
- Target Price
- ENTG $113.22
- MRNA $48.13
- AVG Volume (30 Days)
- ENTG 3.2M
- MRNA 9.8M
- Earning Date
- ENTG 07-30-2025
- MRNA 07-31-2025
- Dividend Yield
- ENTG 0.46%
- MRNA N/A
- EPS Growth
- ENTG N/A
- MRNA N/A
- EPS
- ENTG 2.04
- MRNA N/A
- Revenue
- ENTG $3,243,408,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- ENTG $0.36
- MRNA N/A
- Revenue Next Year
- ENTG $10.11
- MRNA $9.70
- P/E Ratio
- ENTG $42.66
- MRNA N/A
- Revenue Growth
- ENTG N/A
- MRNA N/A
- 52 Week Low
- ENTG $60.75
- MRNA $23.15
- 52 Week High
- ENTG $147.57
- MRNA $129.39
- Technical
- Relative Strength Index (RSI)
- ENTG 63.03
- MRNA 72.66
- Support Level
- ENTG $82.94
- MRNA $29.72
- Resistance Level
- ENTG $88.86
- MRNA $33.65
- Average True Range (ATR)
- ENTG 3.24
- MRNA 1.42
- MACD
- ENTG 0.77
- MRNA 0.63
- Stochastic Oscillator
- ENTG 92.66
- MRNA 89.99
About ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.